Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
3 trials since 2013, 3 ongoing, by the sponsor of the products; see every authorized trial
An extension study to evaluate the long-term safety, tolerability and efficacy of dalfampridine extended-release…May 25, 2015 · Ongoing · Dalfampridine
A double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of two dose strengths of…Dec 22, 2014 · Ongoing · Dalfampridine
A double-blind, placebo-controlled study of AC105 in patients with acute spinal cord injuryApr 10, 2013 · Ongoing · AC105
Payments to doctors (Open Payments)
What this company reported paying US doctors and teaching hospitals each year, $1.2M of it for research; see every company
$4.7M20192019Paid$4.7M
$1.4M20202020Paid$1.4Mvs 2019−$3.3M
$846K20212021Paid$846Kvs 2020−$534K
$396K20222022Paid$396Kvs 2021−$450K
$532K20232023Paid$532Kvs 2022+$135K
$193K20242024Paid$193Kvs 2023−$339K
Orphan designations (FDA)
3 designations since 1983, 1 approved for the designated use, matched by the sponsor's name; see all orphan designations
FampridineTreatment of chronic, incomplete spinal cord injury. · Jun 2, 1997
AmpyraRelief of symptoms of multiple sclerosis · Jun 2, 1987 · approved Jan 22, 2010
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata.